-
Product Insights
Upper Limb Muscle Spasticity - Drugs In Development, 2024
Empower your strategies with our Upper Limb Muscle Spasticity – Drugs In Development, 2024 report and make more profitable business decisions. Spasms or spasticity is a condition in which the stiffening of muscles is seen. Upper limb muscle spasticity is a motor neuron syndrome of the upper extremities. This condition causes voluntary movement impairment following stroke, spinal cord injury, and paralysis. It commonly affects elbows, arms, forearms, wrists and is characterized by muscle stiffness, impaired movement, pain, and reduced ability to...
-
Product Insights
Metachromatic Leukodystrophy (MLD) - Drugs In Development, 2024
Empower your strategies with our Metachromatic Leukodystrophy (MLD) – Drugs In Development, 2024 report and make more profitable business decisions. Metachromatic leukodystrophy (MLD) is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms, especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive. The...
-
Product Insights
Restless Legs Syndrome - Drugs In Development, 2024
Empower your strategies with our Restless Legs Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling, and cramping in the calf or leg muscles. A predisposing factor is age. Treatment includes muscle relaxants, sleep medications, and narcotic medications. The...
-
Product Insights
Myoclonic Seizure - Drugs In Development, 2024
Empower your strategies with our Myoclonic Seizure – Drugs In Development, 2024 report and make more profitable business decisions. Myoclonic seizures cause a quick, uncontrollable muscle movement with no change in level of awareness or consciousness. They are characterized by brief, jerking spasms of a muscle or a group of related muscles, but can sometimes affect wider areas of body. The Myoclonic Seizure drugs in development market research report provide comprehensive information on the therapeutics under development for Myoclonic Seizure, complete...
-
Product Insights
Memory Impairment - Drugs In Development, 2024
Empower your strategies with our Memory Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Memory impairment or memory loss refers to unusual forgetfulness. The person may not be able to remember new events, recall one or more memories of the past, or both. It can occur for a short time and then resolve (transient), or it can persist, and, depending on the cause, worsen over time. The Memory Impairment drugs in development market research report provide...
-
Product Insights
Autoimmune Encephalitis (Post-Infectious) - Drugs In Development, 2024
Empower your strategies with our Autoimmune Encephalitis (Post-Infectious) – Drugs In Development, 2024 report and make more profitable business decisions. Autoimmune encephalitis refers to acute to subacute, progressive inflammation of the brain associated with antibodies against neuronal cell surface and synaptic protein, most commonly being anti - NMDA receptor encephalitis. It is thought to be an autoimmune process with an exaggerated response to a neuronal self-antigen. Unlike paraneoplastic encephalitis, which is a T-cell mediated response, antibodies in AIE are intrinsically pathogenic....
-
Product Insights
Spasmodic Torticollis (Cervical Dystonia) - Drugs In Development, 2024
Empower your strategies with our Spasmodic Torticollis (Cervical Dystonia) – Drugs In Development, 2024 report and make more profitable business decisions. Cervical dystonia, also known as spasmodic torticollis, is a rare neurological disorder that originates in the brain. It is the most common form of focal dystonia in an office setting. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head The Spasmodic Torticollis (Cervical Dystonia) drugs in development...
-
Product Insights
Tardive Dyskinesia - Drugs In Development, 2024
Empower your strategies with our Tardive Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Tardive dyskinesia is a is a movement disorder characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts caused by the blockade of dopamine receptors. The Tardive Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Tardive Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Tonic-Clonic (Grand Mal) Seizure - Drugs In Development, 2024
Empower your strategies with our Tonic-Clonic (Grand Mal) Seizure – Drugs In Development, 2024 report and make more profitable business decisions. A tonic-clonic seizure, previously known as a grand mal seizure, is defined as a seizure that has a tonic phase followed by clonic muscle contractions that causes a loss of consciousness and violent muscle contractions. The Tonic-Clonic (Grand Mal) Seizure drugs in development market research report provide comprehensive information on the therapeutics under development for Tonic-Clonic (Grand Mal) Seizure, complete...
-
Sector Analysis
MELAS Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
MELAS Syndrome Marketed and Pipeline Drugs Report Overview Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes syndrome (MELAS Syndrome) is a progressive multisystem neurodegenerative disorder. It is a rare disorder that begins in childhood, usually between two and 15 years of age, and mostly affects the nervous system and muscles. The MELAS Syndrome marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading products, and pricing and reimbursement of therapy in major countries. Furthermore, the report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.